{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053832","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2026-08-06T11:12:37+00:00","discovered_at":"2026-08-06T11:15:03.438163+00:00","generated_at":"2026-08-06T11:15:14.018914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sionna Therapeutics Q2 2026 net loss $29.9M; cash $268.3M; Phase 2a and Phase 1 trials on track for summer data","bullets":["Net loss of $29.9M for Q2 2026, compared to $18.1M in Q2 2025.","R&D expenses $21.9M (up from $15.4M) and G&A $10.6M (up from $6.5M) driven by pipeline advancement.","Cash and equivalents $268.3M as of June 30, 2026, expected to fund operations into 2028.","PreciSION CF Phase 2a trial of SION-719 as add-on to standard of care on track for topline data summer 2026.","Phase 1 trial of SION-451 in dual combinations with SION-2222 and SION-109 also on track for topline data summer 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053832","json":"https://secwatch.observer/filing/0001628280-26-053832.json","markdown":"https://secwatch.observer/filing/0001628280-26-053832.md","text":"https://secwatch.observer/filing/0001628280-26-053832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/0001628280-26-053832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:15:14.018914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}